Needham & Company

Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

Retrieved on: 
Thursday, March 28, 2024
Floor, Needham & Company, Madison Avenue, Central nervous system, Form, Telephone, CNS, Truist, Sale, Attention, Security (finance), Guggenheim Partners, Form S-3, Praxis, Nicollet Mall

The gross proceeds from the offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis.

Key Points: 
  • The gross proceeds from the offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis.
  • All shares and pre-funded warrants in the offering are being offered by Praxis.
  • In addition, Praxis has granted the underwriters a 30-day option to purchase up to 530,973 additional shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about April 2, 2024, subject to market conditions and the satisfaction of customary closing conditions.

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Retrieved on: 
Wednesday, March 27, 2024
Floor, Needham & Company, Madison Avenue, Central nervous system, Form, Telephone, CNS, Truist, Sale, Attention, Security (finance), Guggenheim Partners, Form S-3, Praxis, Nicollet Mall

All securities in the offering will be offered by Praxis.

Key Points: 
  • All securities in the offering will be offered by Praxis.
  • Piper Sandler, Guggenheim Securities and Truist Securities are acting as joint book-running managers for the offering.
  • The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed.
  • The proposed offering will be made only by means of a preliminary prospectus supplement and the accompanying base prospectus.

Inrad Optics To Be Acquired by Luxium Solutions for $19 Million

Retrieved on: 
Tuesday, April 9, 2024
Engineering, Other Manufacturing, Manufacturing, EST, Form 8-K, Needham & Company, Science, Optics, Acquisition, Capital, INRD, LLP, Disclosure, Investment, Latham & Watkins, Financial services

Inrad Optics, Inc. (OTCMKTS:INRD) (“Inrad Optics” or the “Company”), a provider of advanced optical components, assemblies and systems, today announced that it has entered into a definitive merger agreement to be acquired by Luxium Solutions (“Luxium”), an affiliate of private equity firms SK Capital Partners (“SK Capital”) and Edgewater Capital Partners (“Edgewater”), in an all-cash transaction that values Inrad Optics at approximately $19 million, including assumed debt.

Key Points: 
  • Inrad Optics, Inc. (OTCMKTS:INRD) (“Inrad Optics” or the “Company”), a provider of advanced optical components, assemblies and systems, today announced that it has entered into a definitive merger agreement to be acquired by Luxium Solutions (“Luxium”), an affiliate of private equity firms SK Capital Partners (“SK Capital”) and Edgewater Capital Partners (“Edgewater”), in an all-cash transaction that values Inrad Optics at approximately $19 million, including assumed debt.
  • Following the close of the transaction, Inrad Optics will remain a U.S.-controlled and operated company.
  • Following the closing of the transaction, Inrad Optics expects to benefit from the significant resources, operational expertise and capacity for investment provided by Luxium, SK Capital and Edgewater.
  • “This transaction delivers immediate and certain value to our stockholders,” said Jan Winston, Chair of Inrad Optics’ Board of Directors.

Astera Labs Announces Pricing of Initial Public Offering

Retrieved on: 
Wednesday, March 20, 2024
Data Management, Semiconductor, Communications, Technology, Software, Artificial Intelligence, Public Relations, Investor Relations, J. P. Morgan, Needham & Company, Sale, Attention, Prospectus, Morgan Stanley, Jefferies, Varick Street, Roth Capital Partners, 2nd Floor, Evercore, Capital Group Companies, J.P. Morgan & Co., Security (finance)

Astera Labs, Inc. (“Astera Labs”) today announced the pricing of its initial public offering of 19,800,000 shares of its common stock at a price to the public of $36.00 per share.

Key Points: 
  • Astera Labs, Inc. (“Astera Labs”) today announced the pricing of its initial public offering of 19,800,000 shares of its common stock at a price to the public of $36.00 per share.
  • The offering consists of 16,788,903 shares of common stock offered by Astera Labs and 3,011,097 shares of common stock to be sold by certain of Astera Labs’ existing stockholders.
  • In addition, the underwriters will have a 30-day option to purchase up to an additional 2,970,000 shares of common stock from Astera Labs at the initial public offering price, less underwriting discounts and commissions.
  • The gross proceeds to Astera Labs from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Astera Labs, are expected to be approximately $604.4 million.

Needham Aggressive Growth Fund Wins 2024 LSEG Lipper Fund Award

Retrieved on: 
Friday, March 15, 2024
Banking, Asset Management, Professional Services, Finance, Investment management, Growth, Needham & Company, Financial crisis, Capital loss, Research, Software, Prospectus, Investment, Semiconductor, Power, Fund, Airport

Needham Investment Management , a specialized growth equity manager, today announced that Needham Aggressive Growth Fund has won the 2024 LSEG Lipper Fund Award in the Small-Cap Growth Fund category for delivering consistently strong risk-adjusted performance relative to its peers over five-year period ended November 30, 2023.

Key Points: 
  • Needham Investment Management , a specialized growth equity manager, today announced that Needham Aggressive Growth Fund has won the 2024 LSEG Lipper Fund Award in the Small-Cap Growth Fund category for delivering consistently strong risk-adjusted performance relative to its peers over five-year period ended November 30, 2023.
  • We applaud the 2024 LSEG Lipper Fund Award winners such as Needham Aggressive Growth Fund for delivering outperformance and the accompanying comfort of consistency to investors’ portfolios through a cross-current of global market disruptions.”
    The Needham Group, Inc .
  • LSEG Lipper Awards United States Winner, Needham Aggressive Growth Fund, Best Small-Cap Growth Fund for Five Years among 162 funds in the peer group.
  • This message is not an offer of the Needham Growth Fund, the Needham Aggressive Growth Fund, or the Needham Small Cap Growth Fund (each a “Fund” and collectively, “the Funds”).

Ichor Holdings, Ltd. Announces Pricing of $125 Million Public Offering

Retrieved on: 
Thursday, March 14, 2024
Semiconductor, Engineering, Chemicals, Plastics, Technology, Manufacturing, Hardware, Montgomery Street, Needham & Company, Form, Telephone, Sale, Public expenditure, Attention, Security (finance), Lexington Avenue, Prospectus, Suite, File, ICHR

In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 500,000 of its ordinary shares at the public offering price, less underwriting commissions.

Key Points: 
  • In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 500,000 of its ordinary shares at the public offering price, less underwriting commissions.
  • The offering is expected to close on March 18, 2024, subject to the satisfaction of customary closing conditions.
  • TD Cowen and Stifel are acting as joint book-running managers and representatives of the underwriters for the offering.
  • The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

Ichor Holdings, Ltd. Announces Public Offering of Ordinary Shares

Retrieved on: 
Tuesday, March 12, 2024
Semiconductor, Engineering, Chemicals, Plastics, Technology, Manufacturing, Hardware, Montgomery Street, Needham & Company, Form, Telephone, Sale, Public expenditure, Attention, Security (finance), Lexington Avenue, Prospectus, Suite, File, ICHR

Ichor Holdings, Ltd. (NASDAQ: ICHR), a leader in the design, engineering, and manufacturing of critical fluid delivery subsystems and components for semiconductor capital equipment, today announced that it has commenced an underwritten public offering of $125 million of its ordinary shares.

Key Points: 
  • Ichor Holdings, Ltd. (NASDAQ: ICHR), a leader in the design, engineering, and manufacturing of critical fluid delivery subsystems and components for semiconductor capital equipment, today announced that it has commenced an underwritten public offering of $125 million of its ordinary shares.
  • In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of its ordinary shares sold in the offering at the public offering price, less underwriting commissions.
  • TD Cowen and Stifel are acting as joint book-running managers and representatives of the underwriters for the offering.
  • The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

SeaChange to be Acquired by Partner One

Retrieved on: 
Monday, March 11, 2024
Acquisition, SeaChange, Internal Revenue Code, SeaChange International, OTC, News, XStream, Purchasing, Sales management, Advertising, Computershare, Needham & Company, LLP, Rights, FAST

SeaChange has traditionally supported clients’ Operator TV systems, Advanced Advertising insertion platforms, the StreamVid streaming enablement solution, and the Xstream FAST channel service platform.

Key Points: 
  • SeaChange has traditionally supported clients’ Operator TV systems, Advanced Advertising insertion platforms, the StreamVid streaming enablement solution, and the Xstream FAST channel service platform.
  • The Company currently expects the transaction will result in net proceeds to SeaChange of between $13-15 million upon Closing.
  • In addition, SeaChange may, subject to the terms of the Purchase Agreement, respond to unsolicited, bona fide, written alternative acquisition proposals.
  • Needham & Company, LLC is acting as exclusive financial advisor to SeaChange in this transaction, and K&L Gates LLP is acting as legal counsel to SeaChange in this transaction.

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Retrieved on: 
Monday, March 4, 2024
Varick Street, Attention, Mizuho, Lexington Avenue, Prospectus, Telephone, 2nd Floor, Floor, Sale, Exercise, Form, Morgan Stanley, Madison Avenue, Guggenheim, Needham & Company, Security (finance), Guggenheim Partners, Form S-3

WESTLAKE VILLAGE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the closing of its previously announced underwritten public offering of 18,157,895 shares of common stock at a public offering price of $9.50 per share, which includes 2,368,421 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • WESTLAKE VILLAGE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the closing of its previously announced underwritten public offering of 18,157,895 shares of common stock at a public offering price of $9.50 per share, which includes 2,368,421 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The total gross proceeds of the public offering were approximately $172.5 million, before deducting underwriting discounts and commissions and offering expenses payable by Arcutis.
  • All of the shares in the public offering were sold by Arcutis.
  • Morgan Stanley, TD Cowen, and Guggenheim Securities acted as joint lead bookrunning managers for the offering.

Arcutis Announces Pricing of $150 Million Public Offering

Retrieved on: 
Thursday, February 29, 2024
Varick Street, Attention, Mizuho, Lexington Avenue, Psoriasis, Prospectus, Telephone, Atopic dermatitis, 2nd Floor, Floor, Sale, Form, Morgan Stanley, Madison Avenue, Guggenheim, Needham & Company, S-3, Security (finance), Guggenheim Partners

WESTLAKE VILLAGE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of common stock.

Key Points: 
  • WESTLAKE VILLAGE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of common stock.
  • The shares of common stock are being sold at a public offering price of $9.50 per share.
  • All shares of common stock to be sold in the offering are being offered by Arcutis.
  • The gross proceeds to Arcutis from the offering are expected to be approximately $150.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Arcutis and assuming no exercise of the underwriters’ option to purchase additional shares.